C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
1. C4 Therapeutics presents Phase 1 trial data for cemsidomide at IMS Meeting. 2. Cemsidomide shows promising safety and efficacy in treating multiple myeloma. 3. Company webcast to discuss important clinical developments on September 20, 2025. 4. C4T utilizes the TORPEDO platform for novel therapeutic compounds. 5. Cemsidomide targets drug-resistant cancer proteins, enhancing treatment options.